Fig. 5
In vivo validation of the TB-pTYR::Cre construct system after 4-OHT treatment. (A) Scheme of 4-OHT administration. The skin of an age-matched pig (Control or TB-pTYR::Cre P#1) was shaved, followed by an intradermal injection of 4-OHT. (B) Representative images of skin treated with solvent or 4-OHT via intradermal injection. BT, before treatment. AT, after treatment. Scale bar, 1 cm (C) Quantification of pigmentation after 45 days in sites treated with solvent or 4-OHT via intradermal injection. Data are presented as mean ± SEM. The data were analyzed using Student’s t-test. *p < 0.05. (D) Representative skin histology using H&E staining 45 d post-4-OHT treatment. Black arrow, melanocytic hyperplasia. Scale bar, 100 μm (up) and 30 μm (down). (E) Representative immunofluorescence image of Ki67, MITF, and DsRed expression in TB-pTYR::Cre P#1 skin following solvent and 4-OHT treatment. Scale bar, 150 μm. (F) Quantification of Ki67, MITF, and DsRed expression in TB-pTYR::Cre P#1 skin following solvent and 4-OHT treatment. Data are presented as mean ± SEM, n = 4. The data were analyzed using Student’s t-test. *p < 0.05, ***p < 0.001. (G) Representative immunofluorescence image of BRAFV600E, MITF, and DsRed expression in TB-pTYR::Cre P#1 skin following solvent and 4-OHT treatment. Scale bar, 150 μm. (H) Quantification of BRAFV600E, MITF, and DsRed expression in TB-pTYR::Cre P#1 skin following solvent and 4-OHT treatment. Data are presented as mean ± SEM, n = 4. The data were analyzed using Student’s t-test. *p < 0.05, ****p < 0.0001.
